AI and automation are coming for Texas jobs, according to ChatGPT. Image via Getty Images

ChatGPT seems to have its eyes set on at least 200,000 Texas jobs, according to a new study.

The report by UK-based affiliate marketing site NetVoucherCodes compiled data on nearly 200 U.S. job types and then asked ChatGPT for each job’s relative risk from AI, automation, and also the likelihood of AI increasing that job’s productivity.

The query found that 237,000 jobs in Texas have a high risk of being replaced by AI, and 1.07 million jobs are considered at a medium risk of being replaced by AI.

Similarly 1.8 million Texas jobs were considered at a high risk of being replaced by automation. More than 3 million jobs were considered at a medium risk of being replaced by automation.

In both the AI and automation queries, Texas had the second-most at risk jobs among the states. California had the most jobs at risk in both categories. New York fell behind Texas in the No. 3 spot for most jobs being at risk of being replaced by AI, and Florida had the third most jobs at risk of being replaced by automation.

Maine had the highest number of low-risk jobs, followed by Hawaii and Montana.

Texas jobs that were both at high risk and made up a large portion of Texas's workforce include fast food and counter workers, cashiers, customer service representatives, and stockers and order fillers.

“The data we’ve pulled together shows that a lot of lower income jobs are the ones that are at a higher risk of being replaced. When we break this down, we realize it’s because these jobs often involve a lot of the same repetitive tasks. This can be inputted into a computer and can be done automatically," John Strizaker from NetVoucherCodes said in a statement.

“The jobs that aren’t at risk are ones that really require human thinking and decision making, like nurses, doctors along with creative roles such as fashion designers and hairdressers," he continued.

At the same time, the study found that more than 1.4 million Texas jobs have a high likelihood of being able to use AI and automation to boost productivity. This was the second highest number of jobs in this category behind California.

“Although this might be a concern in the near future, there’s a lot of benefits to AI and automation," Strizaker said in the statement. "It will increase productivity, especially in creative fields and it will be able to take over repetitive tasks and free up workers for other things that require thinking.”

Some Houston companies are already using GPT, or generative pre-trained transformer, technology to their advantage. Femtech company ema pivoted to use the powerful tool to provide access to women's health information 24/7 to its users about 16 months ago.

And at the start of this year the University of Houston and Intel launched a new artificial intelligence program to help bridge the AI knowledge gap and fill hundreds of AI-related jobs that are open in the Houston area.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.